Delcath Systems (NASDAQ:DCTH – Get Free Report) is one of 510 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it weigh in compared to its peers? We will compare Delcath Systems to similar companies based on the strength of its analyst recommendations, dividends, earnings, valuation, institutional ownership, profitability and risk.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Delcath Systems and its peers, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Delcath Systems | 0 | 1 | 2 | 1 | 3.00 |
| Delcath Systems Competitors | 4323 | 10552 | 18356 | 839 | 2.46 |
Delcath Systems presently has a consensus target price of $29.33, suggesting a potential upside of 55.36%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 28.20%. Given Delcath Systems’ stronger consensus rating and higher possible upside, research analysts plainly believe Delcath Systems is more favorable than its peers.
Insider and Institutional Ownership
61.1% of Delcath Systems shares are held by institutional investors. Comparatively, 40.3% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 19.4% of Delcath Systems shares are held by insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Delcath Systems and its peers’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Delcath Systems | 6.05% | 5.56% | 4.98% |
| Delcath Systems Competitors | -191.42% | -197.84% | -21.82% |
Risk & Volatility
Delcath Systems has a beta of 0.62, suggesting that its stock price is 38% less volatile than the S&P 500. Comparatively, Delcath Systems’ peers have a beta of 2.63, suggesting that their average stock price is 163% more volatile than the S&P 500.
Valuation & Earnings
This table compares Delcath Systems and its peers revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Delcath Systems | $85.23 million | $2.70 million | 118.01 |
| Delcath Systems Competitors | $1.90 billion | $138.28 million | 5.93 |
Delcath Systems’ peers have higher revenue and earnings than Delcath Systems. Delcath Systems is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Summary
Delcath Systems beats its peers on 9 of the 13 factors compared.
About Delcath Systems
Delcath Systems, Inc. is an oncology company focused on liver-directed treatments for cancers that have spread to the liver. Its technology uses percutaneous hepatic perfusion, a procedure that temporarily isolates the liver’s blood supply and circulates chemotherapy through the organ before filtering the blood and returning it to the patient. The company’s HEPZATO KIT combines melphalan with a specialized delivery system. The U.S. Food and Drug Administration approved it for certain adults with unresectable metastatic uveal melanoma involving the liver.
Receive News & Ratings for Delcath Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Delcath Systems and related companies with MarketBeat.com's FREE daily email newsletter.
